LLY

753.95

+2.28%↑

JNJ

151.07

+1.12%↑

UNH

291.93

+7.04%↑

ABBV

183.3

+0.85%↑

NVO

64.06

-2.9%↓

LLY

753.95

+2.28%↑

JNJ

151.07

+1.12%↑

UNH

291.93

+7.04%↑

ABBV

183.3

+0.85%↑

NVO

64.06

-2.9%↓

LLY

753.95

+2.28%↑

JNJ

151.07

+1.12%↑

UNH

291.93

+7.04%↑

ABBV

183.3

+0.85%↑

NVO

64.06

-2.9%↓

LLY

753.95

+2.28%↑

JNJ

151.07

+1.12%↑

UNH

291.93

+7.04%↑

ABBV

183.3

+0.85%↑

NVO

64.06

-2.9%↓

LLY

753.95

+2.28%↑

JNJ

151.07

+1.12%↑

UNH

291.93

+7.04%↑

ABBV

183.3

+0.85%↑

NVO

64.06

-2.9%↓

Search

Pfizer

Atvērts

SektorsVeselības aprūpe

22.82 1.06

Pārskats

Akcijas cenas izmaiņa

24h

Šī brīža

Min

22.45

Max

22.78

Galvenie mērījumi

By Trading Economics

Ienākumi

2.6B

3B

Pārdošana

-4B

14B

P/E

Sektora vidējais

16.732

56.602

EPS

0.92

Dividenžu ienesīgums

7.72

Peļņas marža

21.633

Darbinieki

81,000

EBITDA

2B

4.5B

Rekomendācijas

By TipRanks

Rekomendācijas

Pirkt

Prognoze 12 mēnešiem

+26.88% upside

Dividendes

By Dow Jones

Dividenžu ienesīgums

Sektora vidējais

7.72%

2.45%

Nākamie ieņēmumi

2025. g. 29. jūl.

Nākamais dividenžu datums

2025. g. 13. jūn.

Tirgus statistika

By TradingEconomics

Tirgus kapitalizācija

-14B

131B

Iepriekšējā atvēršanas cena

21.76

Iepriekšējā slēgšanas cena

22.82

Ziņu noskaņojums

By Acuity

43%

57%

150 / 382 Rangs Healthcare

Tehniskais rādītājs

By Trading Central

Pārliecība

Bullish Evidence

Pfizer Grafiks

Pagātnes rezultāti nav uzticams nākotnes rezultātu rādītājs.

Saistītās ziņas

2025. g. 1. maijs 18:41 UTC

Galvenie tirgus virzītāji

Arvinas Shares Drop; Cancels Two Drug Trials With Pfizer Amid Capital Markets Challenges

2025. g. 29. apr. 11:24 UTC

Peļņas

Pfizer 1Q Revenue Slides as Paxlovid Sales Fade

2025. g. 15. maijs 15:20 UTC

Top Ziņas

New Allegations About Timing of Pfizer Covid Vaccine Passed to House Panel -- WSJ

2025. g. 12. maijs 22:14 UTC

Top Ziņas

Drugmakers Spared Worst-Case Drug Pricing Scenario for Now -- 2nd Update

2025. g. 12. maijs 18:45 UTC

Top Ziņas

Drugmakers Spared Worst-Case Drug Pricing Scenario for Now -- Update

2025. g. 12. maijs 17:14 UTC

Top Ziņas

Drugmakers Spared Worst-Case Drug Pricing Scenario for Now -- WSJ

2025. g. 12. maijs 09:02 UTC

Karstas akcijas

Stocks to Watch: Amazon, Tesla, Apple, Maersk -- WSJ

2025. g. 7. maijs 17:01 UTC

Top Ziņas

Teva Will Hike Generic Drug Prices If Trump Imposes Tariffs, CEO Says -- Barrons.com

2025. g. 7. maijs 09:30 UTC

Top Ziņas

Trump Is Threatening Big Pharma With Tariffs. Tax Changes Might Work Better. -- Heard on the Street -- WSJ

2025. g. 5. maijs 15:13 UTC

Tirgus saruna
Peļņas

Narrower Guidelines for Covid-19 Booster Wouldn't Limit BioNTech's Customer Base Much -- Market Talk

2025. g. 1. maijs 14:07 UTC

Peļņas

Eli Lilly Earnings Beat Expectations. Why the Stock Is Falling. -- Barrons.com

2025. g. 1. maijs 11:58 UTC

Peļņas

Eli Lilly Earnings Beat Expectations. Why the Stock Is Falling. -- Barrons.com

2025. g. 1. maijs 11:06 UTC

Peļņas

Eli Lilly Earnings Beat Expectations. Why the Stock Is Falling. -- Barrons.com

2025. g. 1. maijs 10:48 UTC

Peļņas

Eli Lilly Earnings Beat Expectations. The Stock Is Falling. -- Barrons.com

2025. g. 29. apr. 19:47 UTC

Peļņas

Pfizer Shares Rise on CEO's Optimism on Threatened Drug Tariffs -- Barrons.com

2025. g. 29. apr. 18:11 UTC

Peļņas

Pfizer Stock's 7% Yield Makes It Look Like a Junk Bond -- But Better -- Barrons.com

2025. g. 29. apr. 15:22 UTC

Peļņas

Pfizer Earnings Beat Isn't Enough to Ease Stock Worries -- Barrons.com

2025. g. 29. apr. 12:03 UTC

Iegādes, apvienošanās, pārņemšana

Pfizer Files 8K - Costs of Exits Or Disposals >PFE

2025. g. 29. apr. 11:46 UTC

Peļņas

Pfizer Stock Gains After Earnings Beat. Tariffs Aren't the Only Worry for Wall Street. -- Barrons.com

2025. g. 29. apr. 11:42 UTC

Peļņas

Pfizer Stock Falls After Earnings Beat. Tariffs Aren't the Only Worry. -- Barrons.com

2025. g. 29. apr. 11:12 UTC

Peļņas

Pfizer Earnings Beat. Tariffs Uncertainty Hinders Guidance. -- Barrons.com

2025. g. 29. apr. 10:52 UTC

Peļņas

Pfizer: Currently Trending Towards Upper End of 2025 Adj EPS Guidance Range

2025. g. 29. apr. 10:51 UTC

Peļņas

Pfizer: Believe We Can Be Agile in Navigating Uncertain and Volatile External Environment

2025. g. 29. apr. 10:50 UTC

Peļņas

Pfizer: On Track For Total Net Cost Savings $5.7B Through 2027

2025. g. 29. apr. 10:47 UTC

Peļņas

Pfizer: Expects to Continue to De-Lever in Prudent Manner

2025. g. 29. apr. 10:47 UTC

Peļņas

Pfizer: Current Fincl Guidance Does Not Anticipate Any Share Repurchases in 2025

2025. g. 29. apr. 10:46 UTC

Peļņas

Pfizer: "Unable to Predict" Tariff Impact "At This Time"

2025. g. 29. apr. 10:45 UTC

Peļņas

Pfizer: Reaffirmed Views Don't Currently Include Impact From Tariffs

2025. g. 29. apr. 10:45 UTC

Peļņas

Pfizer 1Q EPS 52c >PFE

2025. g. 29. apr. 10:45 UTC

Peļņas

Pfizer 1Q Adj EPS 92c >PFE

Salīdzinājums

Cenas izmaiņa

Pfizer Prognoze

Cenas mērķis

By TipRanks

26.88% augšup

Prognoze 12 mēnešiem

Vidējais 27.94 USD  26.88%

Augstākais 32 USD

Zemākais 24 USD

Pamatojoties uz 18 Volstrītas analītiķiem, kuri piedāvā 12 mēnešu cenu mērķi Pfizer  — pēdējo 3 mēnešu laikā.

Vērtējuma vienprātība

By TipRanks

Pirkt

18 ratings

5

Pirkt

13

Turēt

0

Pārdot

Tehniskais rādītājs

By Trading Central

22.855 / 23.85Atbalsts un pretestība

Īstermiņā

Bullish Evidence

Vidējā termiņā

Bearish Evidence

Ilgtermiņā

Bearish Evidence

Noskaņojums

By Acuity

150 / 382 Rangs Veselības aprūpe

Ziņu noskaņojums

Liecība "Buļļu" tendencei

Volatilitāte

Zem vidējā

Ziņu apjoms (RCV)

Zem vidējā

Finanšu rādītāji

Pārdošanas un administrēšanas izmaksas

Darbības izmaksas

Peļņa pirms nodokļu nomaksas

Pārdošana

Pārdošanas maksa

Bruto peļņa no pārdošanas

Procentu izdevumi par parādu

EBITDA

Pamatdarbības peļņa

$

Par Pfizer

Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands. It also provides medicines and vaccines in various therapeutic areas, such as biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, Litfulo, Velsipity, and Cibinqo brands; amyloidosis, hemophilia, endocrine diseases, and sickle cell disease under the Vyndaqel family, Oxbryta, BeneFIX, Somavert, Ngenla, and Genotropin brands; sterile injectable and anti-infective medicines under the Sulperazon, Medrol, Zavicefta, Zithromax, and Panzyga brands; and biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Inlyta, Bosulif, Mektovi, Padcev, Adcetris, Talzenna, Tukysa, Elrexfio, Tivdak, Lorbrena, and Braftovi brands. In addition, the company involved in the contract manufacturing business. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, individual provider offices, retail pharmacies, and integrated delivery systems. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Merck KGaA; and BioNTech SE, as well as has strategic clinical collaboration with Acepodia Inc. for the development of antibody-cell conjugation-based cell therapies in autoimmune diseases. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.